Altan Pharma Ltd. announced this week the signing of a licensure agreement that will commercialize a generic version of caspofungin.
The newly signed agreement grants commercialization rights for Germany, France, Italy, Spain, the United Kingdom, Belgium, Portugal, Poland and Latin American.
Caspofungin is an antifungal medication designed to treat adult and pediatric patients with invasive candidiasis. It was also developed for the treatment of adult and pediatric patients with invasive aspergillosis who resist amphotericin B. Caspofungin is also meant as a therapy for patients who are febrile and neutropenic with fungal infections.
The agreement on a generic form of caspofungin brings Altan one step closer to its goal of developing a strong collection of injectable medications it can provide to Europe as well as other markets around the world. Altan is committed to increasing its global reach by creating a network through future in-licensing and acquisitions.
In 2015 the IMS Institute for Health Care Informatics reported that the caspofungin market in Europe was nearly €260 million as covered by the agreement.